This could reduce the number of non pregnant women included in the Phase I trials. Second, slower enrollment into stand-alone Phase I trials might delay the availability of the product for pregnant women relative to the general population. Third, for any number of reasons, the stand-alone Phase I trials in pregnant women may never be initiated.